Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Entry into a Material Definitive Agreement
Item1.01.
| Entry into a Material Definitive Agreement |
784 Memorial Drive Lease
On May31, 2017, Infinity Pharmaceuticals, Inc. (we,
us, or our) and BHX, LLC, as trustee of 784 Realty
Trust (the Landlord), entered into a third amendment (the
Third Lease Amendment) to that certain lease dated
September25, 2014 (as amended, the Lease) for the lease of
office space at 784 Memorial Drive, Cambridge, MA 02139 (the
Premises). The Third Lease Amendment extends the first
amendment to the Lease (the First Lease Amendment),
effective as of March27, 2017, under which we and Landlord agreed
to the early termination of the Lease subject to the satisfaction
of specified contingencies and payment of a termination payment,
as described in more detail below.
Under the Third Lease Amendment, the Lease will terminate
effective August31, 2017 (the Early Termination Date) upon
satisfaction of the following contingencies: (i)we receive from
Landlord a notice (Landlord Notice) on or before June22,
2017 that it entered into a new lease or leases on or before
June15, 2017 with respect to 50% of the Premises (the Landlord
Contingency), or that it has waived the Landlord Contingency;
(ii)we provide notice to Landlord on or before June22, 2017
(Tenant Notice) that we received a qualifying lender
consent on or before June15, 2017 (the Tenant Contingency)
or that we have waived the Tenant Contingency; and (iii)our
payment to Landlord of $5,000,000 in the manner described in the
First Lease Amendment.
If the Landlord Notice is not timely given, the Third Lease
Amendment shall be null and void, and the Lease shall remain in
effect in accordance with its terms as they existed immediately
prior to execution and delivery of the Third Lease Amendment.
The foregoing description of the terms of the Third Lease
Amendment does not purport to be complete and is qualified in its
entirety by reference to the full text of the Third Lease
Amendment, a copy of which is attached hereto as Exhibit 10.1 to
this Current Report on Form 8-K.
| Item9.01. | Financial Statements and Exhibits. |
(d) The following exhibit is included in this report:
|
Exhibit No. |
Description |
|
| 10.1 |
Third Amendment to Lease, effective as of May31, 2017, between Infinity Pharmaceuticals, Inc. and BHX, LLC as trustee of 784 Realty Trust. |
About Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Recent Trading Information
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) closed its last trading session up +0.14 at 1.86 with 252,150 shares trading hands.